文献库搜索 | GeneLibs

Tidswell(R),Owen(C),Shafey(M),Perry(S),Cox... Eur J Haematol 2026-06-00

...TP53 mutation (84% vs. 16%, p = 0.0002), age > 75 years (66% vs. 34%, p = 0.0051), and residence > 100 km from an obinut...

Yang(Z),Li(T),Shen(J),Huang(Y),Lei(C),Yu(J... BMC Cancer 2026-02-16

...TP53, CTNNB1, or TERT. In parallel, germline susceptibility variants identified by genome-wide association studies (GWAS...

Wei(J),Zhang(R),Li(J),Li(S),Yan(X),Chen(H)... Oncologist 2026-03-09

...TP53, KMT2D, TERT, CDKN2A/B, and FGFR3. ORR reached 75.0% in SMARCA4-mutated tumors and 50.0% in NECTIN4-amplified cases...

Maclachlan(KH),Tan(CR),Shekarkhand(T),Rued... Blood Adv 2026-04-28

...TP53 mutations and considers the co-occurrence of immunoglobulin H translocations with chromosome 1 aberrations. Given t...

Schluga(PHC),Boia-Ferreira(M),Theodoro(JL)... Adv Biol Regul 2026-05-00

...TP53, STAT3, and c-JUN. Prolonged exposition to the toxin demonstrated modulation of some of these pathways related to c...

Onyenobi(E),Zhong(M),Peitz(J),Chawla(K),Pl... Hum Genomics 2026-02-21

...TP53, BCL2, STAT3, ESR1, and MYC. RFE with XGBoost identified a 26-miRNA panel for multiclass classification and a 4-miR...

Chu(S),Skidmore(ZL),Warren(W),Fisk(B),Kim(... Vet Comp Oncol 2026-06-00

...TP53 harboured consequential variants in 71% of the FOSCC tumours and was the most commonly mutated gene. Consequential ...

Shen(K),Liu(D),Su(J),Shen(S),Zhang(H),Xu(W... Front Cell Dev Biol None

...TP53 network dysregulation, and metabolic reprogramming of taurine and pantothenate/CoA pathways. TRIM26-low tumors were...

Liang(L),Wang(W) Front Immunol None

...tp53 is highly context-dependent, shaped by co-mutations and tissue origin. In TP53/KRAS co-mutant non-small cell lung c...

Chen(K),Zhang(L),Wu(R),Wei(J),Yang(K),Luo(... Front Oncol None

...TP53 biallelic inactivation, HLA locus alterations, and persistent LOC285045 fusions. Drug sensitivity profiling suggest...